The DOI matches its Crossref record; 63 of the 64 references it cites were found in a registry or an index, and 1 are not checked yet; 15 of the 51 sources its claims cite were checked for support.
MicroRNA 21 Promotes Glioma Invasion by Targeting Matrix Metalloproteinase Regulators
Open accessAbstract
Substantial data indicate that microRNA 21 (miR-21) is significantly elevated in glioblastoma (GBM) and in many other tumors of various origins. This microRNA has been implicated in various aspects of carcinogenesis, including cellular proliferation, apoptosis, and migration. We demonstrate that miR-21 regulates multiple genes associated with glioma cell apoptosis, migration, and invasiveness, including the RECK and TIMP3 genes, which are suppressors of malignancy and inhibitors of matrix metalloproteinases (MMPs). Specific inhibition of miR-21 with antisense oligonucleotides leads to elevated levels of RECK and TIMP3 and therefore reduces MMP activities in vitro and in a human model of gliomas in nude mice. Moreover, downregulation of miR-21 in glioma cells leads to decreases of their migratory and invasion abilities. Our data suggest that miR-21 contributes to glioma malignancy by downregulation of MMP inhibitors, which leads to activation of MMPs, thus promoting invasiveness of cancer cells. Our results also indicate that inhibition of a single oncomir, like miR-21, with specific antisense molecules can provide a novel therapeutic approach for "physiological" modulation of multiple proteins whose expression is deregulated in cancer.
Verified 2026-10-19 · 1 reference not checked yet
Overview
AI snapshot
Written from the paper’s full text.
TL;DR
miR-21 is elevated in high-grade gliomas and promotes glioma invasion by directly targeting the MMP inhibitor RECK and indirectly regulating TIMP3, leading to increased MMP activity. Inhibiting miR-21 raises RECK/TIMP3, reduces MMP activity in vitro and in vivo, and decreases glioma cell motility and invasion, partly rescued by RECK knockdown.
Key findings
- miR-21 levels remain low in grade II gliomas and most grade III tumors but are significantly higher in GBMs; RECK mRNA is significantly lower in GBMs than normal brain and grade II/III gliomas, and TIMP3 mRNA tends to be lower in GBMs.
- Anti-miR-21 treatment changed expression of ∼570 genes (P < 0.05); upregulated transcripts were enriched for miR-21 seed hexamers (expectations 1.45e−09, 1.37e−14, and 1.82e−12), and at least 65 mRNAs were upregulated by anti-miR-21 and downregulated by miR-21 overexpression.
- miR-21 inhibition increased RECK mRNA ∼2-fold and TIMP3 mRNA about 1.6-fold; RECK was validated as a direct miR-21 target by luciferase reporter, whereas TIMP3 was not consistently directly responsive and is likely downstream.
- miR-21 inhibition reduced MMP-2 activity in A172 and U87 cells and lowered MMP activity in U87 subcutaneous tumors in nude mice; it also reduced scratch motility and Matrigel invasion, with reduced motility partly rescued by RECK siRNA and reduced invasion not observed when anti-miR-21 was cotransfected with RECK siRNA.
Methods
- Human glioma cell lines A172, U87, and LN229 (high miR-21), plus HeLa, MCF7, and U2OS cells, and human nonneoplastic brain and tumor samples; cells were transfected with 2′-O-MOE anti-miR-21, mismatch/control oligonucleotides, synthetic miR-21 duplex, or RECK siRNA.
- mRNA profiling used Agilent 44K arrays at 6 and 24 h posttreatment, with qRT-PCR, Western blot, luciferase 3′ UTR reporter assays with mutated miR-21 binding sites, gelatin zymography, scratch migration, and Matrigel invasion assays.
- In vivo, U87 cells transfected with anti-miR-21 or control were implanted subcutaneously in nude mice; MMP activity was imaged with MMPSense 680 at 3 days after implantation and 24 h later, with caliper tumor measurements.
Limitations
- Stated by the authors: the 2′-O-MOE anti-miR-21 did not significantly or consistently change glioma cell viability or reduce subcutaneous U87 tumor growth; subcutaneous U87 tumors are noninfiltrative, noninvasive, and poorly vascularized, so they are not an accurate model for studying invasiveness and tumor growth; nucleic acid chemistry can profoundly alter cellular responses to miRNA inhibition; therapeutic potential requires future research.
- Stated/evident from the text: the TIMP3 3′ UTR reporter did not consistently respond to miR-21 changes, so TIMP3 is likely a downstream effector rather than a direct target; RECK protein bands were not detectable by Western blot in U87 cells despite ∼2-fold RECK mRNA upregulation.
- Evident from the text: in vivo imaging was performed within the first week, when anti-miR-21 did not affect subcutaneous U87 tumor growth; comparison with a prior intracranial LNA-DNA anti-miR-21 study is limited because tumor locations differed.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
15 of 51 cited sources checked · 11 supported · 0 flagged · accuracy not yet measured
Every source the paper cites for this claim was checked and supports it.
In the paper
“Among the molecules tested, the 2′-O-MOE ASO was the most potent in repressing miR-21 activity (Fig. 2A), in agreement with previous data (10), whereas the uniform 2′-O-methyl ASO was the least potent, and mixed locked nucleic acid (LNA)-DNA oligonucleotides were variable (data not shown).”
What the sources say
- Supportedcites [10] source
The Discussion explicitly identifies the uniformly modified 2′-O-MOE-PO oligonucleotide as the best anti-miRNA ASO tested. This supports the attributed comparison for miR-21 activity, although the passage specifies the oligonucleotide’s backbone as PO. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Concurring with previously published reports (12, 46), our data indicate that these MMP inhibitors regulate MMP activity posttranslationally.”
What the sources say
- Supportedcites [12] source
The paper describes TIMPs as inhibitors of metalloproteinase activity and shows that TIMP-3 controls the cell-surface activation of pro-MMP-2 (Abstract and Discussion; page numbers unavailable). Its gene-expression analysis found comparable MMP-2 levels in wild-type and TIMP-3-deficient cells despite altered processing, supporting regulation after translation. (LLM, conf=0.91)
- Not checked — no full text of the sourcecites [46] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes- Rests on an assumption: MMPs are a group of peptidases involved in degradation of the ECM.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“However, we have not detected any correlation between miR-21-modulated expression in several glioma cell lines and protein level of phosphatase and tensin homolog (data not shown), the reported miR-21 target in hepatocellular carcinomas (44).”
What the sources say
- Supportedcites [44] source
The citation supports the identification of PTEN as a reported miR-21 target in hepatocellular carcinoma: the Results state that PTEN was shown to be a direct target of miR-21 in HCC cells. The preceding statement about no correlation in glioma cell lines is the citing authors’ own unpublished observation, not a finding attributed to this source. (LLM, conf=0.94)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Our data suggest that this can be at least partly due to miR-21 regulation, in addition to the reported chromosome 12q22-23 loss of heterozygosity and hypermethylation (56).”
What the sources say
- Partly supportedcites [56] Watanabe T., 2003, Brain Pathol. sourceExperimental — accuracy not yet measured
The Abstract (page unavailable) reports chromosome 12q22–23 loss of heterozygosity in glioblastomas and its association with low Apaf-1 expression. It mentions hypermethylation only as a possible mechanism in some malignancies; the reported study did not measure it in glioblastomas. The miR-21 proposal is presented as the citing authors’ own conclusion, not as a finding attributed to this source. (LLM, conf=0.83)
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“In gliomas, APAF1 is often inactivated or downregulated (56).”
What the sources say
- Partly supportedcites [56] Watanabe T., 2003, Brain Pathol. sourceExperimental — accuracy not yet measured
The Abstract reports low APAF1 mRNA and protein expression in many glioblastomas with chromosome 12q22–23 loss of heterozygosity. The study examined glioblastoma, however, so it does not establish that APAF1 is often inactivated or downregulated across gliomas generally. (LLM, conf=0.85)
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passes- Partly supported
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The numbers of invasive A172 and U87 cells in cultures with inhibited miR-21 were significantly reduced relative to those in cultures transfected with the control oligonucleotide (Fig. 7A and B).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“Specific inhibition of miR-21 with antisense oligonucleotides leads to elevated levels of RECK and TIMP3 and therefore reduces MMP activities in vitro and in a human model of gliomas in nude mice.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, downregulation of miR-21 in glioma cells leads to decreases of their migratory and invasion abilities.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK mRNA expression was significantly lower in GBMs than in normal brain tissue and, especially, in grade II and III gliomas.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesA result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“When miR-21 was suppressed, the amount of gelatin digested that reflects the levels of MMP-2 proteolytic activity was significantly reduced relative to the amount for the cells transfected with the control oligonucleotide (Fig. 5A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passes
- It may state two separate claims as one. 28
- Probably not a substantial claim. 21
- The quote only partly states this claim. 2
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Accumulated data suggested that MMP levels and activities are significantly elevated in human gliomas, which contributes to glioma cell invasion of the surrounding normal tissues, metastasis, and angiogenesis through cell surface ECM degradation (21, 45).”
What the sources say
- Not checked — no full text of the sourcecites [21] Hu B., 2003, Proc. Natl. Acad. Sci. USA source
- Partly supportedcites [45] sourceExperimental — accuracy not yet measured
The Abstract and §4.1 link elevated MMP levels in human gliomas to invasiveness, and describe ECM degradation and cell-surface activation. But the Abstract discusses metastasis in cancer generally, not specifically gliomas; §4.2 links MMP-9 to angiogenesis only tentatively and says its activity in invasive glioma tissue is unproven. The copy therefore does not establish significantly elevated MMP activities across human gliomas or the claimed glioma metastasis and angiogenesis mechanism. Page numbers were not supplied. (LLM, conf=0.88)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MMPs are a group of peptidases involved in degradation of the ECM.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“TIMP3 is a tissue inhibitor of MMPs that inhibits angiogenesis and tumor cell infiltration and also induces apoptosis (2, 48).”
What the sources say
- Partly supportedcites [2] sourceExperimental — accuracy not yet measured
The paper’s Summary (p. 1347) identifies TIMP-3 as a tissue inhibitor of metalloproteinases, and its discussion reports inhibited invasion of HeLa and HT1080 cancer cells and apoptotic death in three cancer cell lines. The copy does not report that TIMP-3 inhibits angiogenesis; searches for angiogenesis and blood-vessel formation found no supporting passage. (LLM, conf=0.88)
- Not checked — no full text of the sourcecites [48] source
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim. It may state two separate claims as one.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“This microRNA has been implicated in various aspects of carcinogenesis, including cellular proliferation, apoptosis, and migration.”
- Also stated in: § Abstract · plain
“miR-21 has been identified in controlling apoptosis, cell proliferation, and migration of cell lines in breast, colorectal, and other cancers (1, 44, 51, 59).”
What the sources say
- Not checked — no full text of the sourcecites [1] source
- Supportedcites [44] source
The Results report that changing miR-21 expression affects proliferation and migration in HCC cells. The Discussion also reports anti-apoptotic properties of miR-21 in glioblastoma and cholangiocarcinoma, supporting the broader statement that it has been implicated in all three processes. (LLM, conf=0.92)
- Not checked — no full text of the sourcecites [51] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Also stated in: § Abstract · plain
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Our analysis also confirmed tropomyosin 1 (TPM1) regulation by miR-21, previously reported to occur in MCF7 cells (59, 60).”
What the sources say
- Supportedcites [59] source
The Abstract reports that experiments using tumors derived from MCF-7 cells identified TPM1 as a miR-21 target and confirmed that miR-21 down-regulates its expression. The Results section also reports increased endogenous TPM1 in anti-miR-21-treated, MCF-7-derived tumors. The paper therefore supports the cited prior report, although its tumor measurements were made in MCF-7-derived tumors rather than isolated cells. (LLM, conf=0.90)
- Not checked — no full text of the sourcecites [60] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Another factor that can induce miR-21 expression is hypoxia, a general feature of all solid tumors (30).”
What the sources say
- Supportedcites [30] source
The Results report miR-21 among the hypoxia-regulated microRNAs and say its microarray result was checked by quantitative RT-PCR. The introductory passage describes hypoxia as an essential feature of the neoplastic microenvironment. (LLM, conf=0.90)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“The miR-21 gene contains two conserved STAT3 binding sites within its enhancer region and is induced by interleukin 6 (IL-6) in a STAT3-dependent way.”
What the sources say
- Supportedcites [39] source
The Results and discussion section identifies two conserved Stat3 binding sites in the miR-21 upstream regulatory region. It also reports that IL-6 increased miR-21 expression and that Stat3 knockdown inhibited this induction. (LLM, conf=0.94)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“MMPs can degrade ECM components and therefore play important roles in mediating GBM tumor cell motility and invasion (45).”
What the sources say
- Supportedcites [45] source
The Introduction says MMPs can degrade nearly all ECM macromolecules in the brain and are believed to play a major role in tumor invasion. The Abstract links MMP-mediated ECM degradation to glioblastoma invasion, while Section 4 describes how ECM degradation may permit glioma-cell migration. (LLM, conf=0.92)
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“APAF1 (apoptotic protease activating factor 1) is the molecular core of apoptosome. It is typically required for activation of the caspases that initiate apoptosis (3, 26).”
What the sources say
- Supportedcites [3] source
The Introduction describes Apaf-1 oligomerization as forming the apoptosome, while the Results and discussion state that Apaf-1 normally recruits and activates caspases-9 and -3. The Concluding remarks add that caspase-9 activity depends on interaction with oligomerized Apaf-1. Page numbers are not provided in our copy. (LLM, conf=0.90)
- Supportedcites [26] Johnson C. E., 2007, Proc. Natl. Acad. Sci. USA source
The paper’s introductory discussion (page not specified in our copy) says cytochrome c binds Apaf-1, leading to recruitment of procaspase-9 and formation of the apoptosome; the apoptosome then activates caspase-9. In the section on Apaf-1 expression levels (page not specified), adding Apaf-1 enabled cytochrome c to activate caspases in neural extracts, supporting its required role in the pathway described. (LLM, conf=0.91)
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
- Supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Elevated miR-21 expression has been causally linked to proliferation, apoptosis, and migration of several cancer cell lines (1, 5, 44, 60).”
What the sources say
- Not checked — no full text of the sourcecites [1] source
- Not checked — no full text of the sourcecites [5] source
- Supportedcites [44] source
The Results report that experimentally increasing or inhibiting miR-21 changed proliferation and migration in HCC cell lines. The Discussion reports anti-apoptotic properties of miR-21 in glioblastoma and cholangiocarcinoma, supporting the apoptosis part as a finding the paper reports from other studies. (LLM, conf=0.87)
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“miR-21 levels remain low in grade II gliomas and in most grade III tumors and are significantly higher in GBMs (Fig. 1).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“This expression pattern is different from those of the other cancer-associated miRNAs, for example, miR-10b, which is often elevated in grade III and even grade II gliomas (Fig. 1) and dysregulated in some other cancers (41).”
What the sources say
- Not checked — no full text of the sourcecites [41] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“RECK mRNA level increased consistently ∼2-fold and TIMP3 mRNA about 1.6-fold in the cells transfected with anti-miR-21.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These experiments demonstrated that inhibition of miR-21 reduced the motility of glioma cells (Fig. 6B and C).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“We note that, though 2′-O-MOE miR-21 ASO induced many proapoptotic and cell cycle arrest genes (Fig. 2C; also see Table S1 in the supplemental material), it did not significantly and consistently change the viability of glioma cell lines, which was reported for other, less potent miR-21 inhibitors (5, 8).”
What the sources say
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“STAT3, the other gene that may play a tumor suppressor function in GBM (11), is also negatively regulated by miR-21 according to the microarray data (see Table S1 in the supplemental material) and is a predicted miR-21 target (29, 34).”
What the sources say
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As identified in our study, TIMP3 or both TIMP3 and RECK are also induced by anti-miR-21 in MCF7 (breast carcinoma) and U2OS (osteosarcoma) cells (Fig. 4D).”
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In glioma progression from less invasive grade II gliomas to very invasive GBMs, RECK and TIMP3 levels drop (Fig. 4B), whereas miR-21 expression increases (Fig. 1).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Here, we show that a 2′-O-MOE ASO not only is potent but also upregulates miR-21 seed-containing mRNAs (Fig. 2 and 3).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Substantial data indicate that microRNA 21 (miR-21) is significantly elevated in glioblastoma (GBM) and in many other tumors of various origins.”
- Also stated in: § Abstract · boosted
“Using high-throughput profiling of miRNA expression, we have previously identified a specific miRNA, miRNA 21 (miR-21), as most strongly elevated in nearly all analyzed human GBM specimens (5).”
- Also stated in: § Abstract · boosted
“Other groups demonstrated overexpression of this miRNA in a wide range of other cancers, including breast, lung, colon, prostate, pancreas, ovarian, and stomach cancers, as well as in chronic lymphocytic leukemia (33, 54).”
What the sources say
Strength:boosted· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
- Also stated in: § Abstract · boosted
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“mRNAs carrying RECK and TIMP3 are predicted conserved miR-21 targets with one and two putative binding sites, respectively (Fig. 4A).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“The sequences of the control and mismatch oligonucleotides have been analyzed using BLAST searches to exclude potential hits in the human transcriptome.”
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“RECK is a membrane-anchored MMP inhibitor whose reduced expression or inactivation seems to be critical for the invasiveness and metastasis of various cancers, including glioma cancer (7, 46).”
What the sources say
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“The high level of miR-21 expression in GBMs compared to that in anaplastic astrocytomas suggests the involvement of miR-21 in one of these key processes.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesThe quote only partly states this claim.
In the paper
“Its expression level is also an important prognostic factor for multiple cancer types (6).”
What the sources say
- Not checked — no full text of the sourcecites [6] source
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“It has been demonstrated to inhibit MMP activity and tumor growth in malignant gliomas in vivo (31, 32).”
What the sources say
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Since modified oligonucleotides can induce a wide range of nonspecific, off-target-mediated effects, several ASO molecules of different chemistries have been used for miR-21 inhibition.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our data suggest that miR-21 contributes to glioma malignancy by downregulation of MMP inhibitors, which leads to activation of MMPs, thus promoting invasiveness of cancer cells.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
- Rests on an assumption: MMPs are a group of peptidases involved in degradation of the ECM.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Such overrepresentation of the hexamers suggests an abundance of direct miR-21 targets among the genes upregulated by 2′-O-MOE anti-miR-21 and indicates that the effects of this molecule on glioma cells are indeed mediated through the miR-21 pathway.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“These experiments have been performed with the miR-21 inhibitor and with a mismatched control oligonucleotide to ensure that any observed effects are driven by miR-21.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
In the paper
“Importantly, it inhibits tumor necrosis factor alpha-converting enzyme and induces apoptosis through the stabilization of tumor necrosis factor alpha receptors on the cell surface (42).”
What the sources say
- Not checked — no full text of the sourcecites [42] source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Moreover, it leads to reduction of glioma cell motility and invasion, which is mediated by elevated RECK expression and was partly rescued by RECK siRNA (Fig. 6 and 7).”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“This implies that miR-21 regulates RECK and TIMP3 expression and thus MMP activities and glioma tumor invasiveness.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In this study, we have demonstrated in vitro and in vivo, using U87 glioma xenografts in nude mice, that miR-21 regulates MMPs and glioma cell invasiveness by directly controlling the MMP inhibitor RECK.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“These combined results indicate that miR-21 regulates overlapping though not identical sets of genes in different cells and therefore shares common signaling pathways in different cancers.”
Strength:hedged· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
The paper states this without a source or data behind it here, so there is nothing to check it against. The quote shows it is in the paper.
In the paper
“The APAF1 3′ UTR contains a strong miR-21 binding site (9-mer binding at miR-21 5′ end), and therefore, it is likely one of the direct miR-21 targets.”
Strength:hedged· not yet calibratedCausal:conditional· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes? Load-bearing: unclear✓ Based: passesIt may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“Its expression is highly upregulated in a variety of solid tumors, including GBM, breast, lung, colon, prostate, pancreas, and stomach cancers (5, 54).”
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A conclusion the paper draws from its own results — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Our mRNA expression analysis suggests that miR-21 regulates the expression of multiple mRNA targets and thereby induces several cellular programs in glioma cells, including those associated with the tumor invasiveness and microvascular proliferation typical for the GBM as well as those involved in cell cycle regulation and apoptosis.”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“Its ectopic expression in glioma cells induces upregulation of genes associated with angiogenesis, growth factors, cytokines, death receptors, and substrates of the various MMPs (31).”
What the sources say
- Not checked — no full text of the sourcecites [31] Lam P., 2005, Mol. Ther. source
Strength:plain· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“RECK, a membrane-anchored regulator, and TIMP3, the ECM-bound protease regulator, are key inhibitors of several MMPs, and their expression is prognostic in a number of common cancers (28, 53).”
What the sources say
Strength:plain· not yet calibratedCausal:correlational· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
A claim is checked only against the cited paper’s full text, never its abstract, and none is available for its sources.
In the paper
“TIMP3 has been demonstrated to activate caspases and therefore induce apoptosis of human glioma cells in vitro and the growth inhibition of human glioma tumors in a mouse model (31, 32).”
What the sources say
Strength:boosted· not yet calibratedCausal:direct· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it. It may state two separate claims as one.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Though mRNA expression analysis does not allow identification of targets whose translation is regulated without modulation of mRNA levels”
Load-bearingStrength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesProbably not a substantial claim.
What the paper did — it cites no source for this, so there is none to check. The quote shows it is in the paper.
In the paper
“Such a bidirectional approach to manipulating miR-21 levels enabled narrowing of the lists of regulated genes and identification of those whose expression correlated negatively with miR-21 levels”
Tests✓ Asserted: passes✓ Checkable: passes✓ Load-bearing: passes✓ Based: passesIt may state two separate claims as one.
In the paper
“In these experiments, we used tumorigenic U87 cells, a common model of human gliomas (23).”
What the sources say
- Not checked — no full text of the sourcecites [23] source
Strength:plain· not yet calibratedTests✓ Asserted: passes✓ Checkable: passes✗ Load-bearing: fails✓ Based: passesProbably not a substantial claim. The paper’s conclusions may not depend on it.
The paper relies on this without support.
MMPs are a group of peptidases involved in degradation of the ECM.
“MMPs are a group of peptidases involved in degradation of the ECM.”
The paper relies on this without support.
Subcutaneous U87 tumors are noninfiltrative, noninvasive, and poorly vascularized.
“We should also note that subcutaneous U87 tumors are noninfiltrative, noninvasive, and poorly vascularized.”
The paper relies on this without support.
Knowledge of the molecular mechanisms mediating miR-21 function in cancer generally and in gliomas specifically is limited.
“However, our knowledge of the molecular mechanisms mediating miR-21 function in cancer generally and gliomas specifically is limited.”
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“miR-21 is a well-known miRNA, found to be overexpressed in almost all cancer types, where its upregulation promotes cell proliferation, invasion, and metastatic behavior.”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [17]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Previous studies have proven that PDCD4, HNRNPK and RECK are TSGs among the direct targets of miR-21-5p (13,(27)(28)(29).”
From Functional interaction between miR-505-3p and miR-21 contributes to GBM suppression (2026) · cites this paper as [28]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“miR-21 targets several genes such as PDCD4, TIMP3, and RECK, which are key regulators of apoptotic and metastatic pathways (17–23).”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [17]
The cited source says what the claim attributes to it.
In the citing paper
“Our data on the effects of miR-21 enriched exosomes is in agreement with the previous reports demonstrating that overexpressed miR-21 in cell lines can increase the proliferation rate and malignant behavior of the cells (17–23).”
From Potential Therapeutic Effects of Exosomes Packed With a miR-21-Sponge Construct in a Rat Model of Glioblastoma (2019) · cites this paper as [17]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
APAF1 overexpression claim cites a caspase-8 study
MinorIn the APAF1 discussion, the paper attributes apoptosis induced by viral overexpression to APAF1 and cites reference 50. The cited reference instead describes adenovirus-mediated transfer of caspase-8 in combination with a superrepressor of NF-kappaB.
“Its overexpression by viral transduction induces apoptosis in glioma cells and may be beneficial in glioma treatment (50).”
“50.Shinoura, N., N. Yamamoto, Y. Yoshida, A. Asai, T. Kirino, and H. Hamada. 2000. Adenovirus-mediated transfer of caspase-8 in combination with superrepressor of NF-kappaB drastically induced apoptosis in gliomas.”
Citations
Cites
Analysis of Relative Gene Expression Data Using Real-Time Quantitative PCR and the 2−ΔΔCT Method
Livak, K. J., & Schmittgen, T. D. (2001) · Methods · doi:10.1006/meth.2001.1262 · Cited by 180,860
Lewis, B. P., Burge, C. B., & Bartel, D. P. (2005) · Cell · doi:10.1016/j.cell.2004.12.035 · Cited by 11,855
Oncomirs—MicroRNAs with a role in cancer
Esquela-Kerscher, A., & Slack, F. J. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1840 · Cited by 5,884
A microRNA expression signature of human solid tumors defines cancer gene targets
Volinia, S., Calin, G. A., Liu, C.-G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., Roldo, C., Ferracin, M., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0510565103 · Cited by 5,697
Summaries of Affymetrix GeneChip probe level data
Irizarry, R. A. (2003) · Nucleic Acids Research · doi:10.1093/nar/gng015 · Cited by 4,837
Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs
Lim, L. P., Lau, N. C., Garrett-Engele, P., Grimson, A., Schelter, J. M., Castle, J., Bartel, D. P., Linsley, P. S., & Johnson, J. M. (2005) · Nature · doi:10.1038/nature03315 · Cited by 4,755
Self-citationIn vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro
Liang, C.-C., Park, A. Y., & Guan, J.-L. (2007) · Nature Protocols · doi:10.1038/nprot.2007.30 · Cited by 4,696
Combinatorial microRNA target predictions
Krek, A., Grün, D., Poy, M. N., Wolf, R., Rosenberg, L., Epstein, E. J., MacMenamin, P., da Piedade, I., Gunsalus, K. C., Stoffel, M., et al. (2005) · Nature Genetics · doi:10.1038/ng1536 · Cited by 4,603
miRBase: microRNA sequences, targets and gene nomenclature
Griffiths-Jones, S. (2006) · Nucleic Acids Research · doi:10.1093/nar/gkj112 · Cited by 3,950
John, B., Enright, A. J., Aravin, A., Tuschl, T., Sander, C., & Marks, D. S. (2004) · PLoS Biology · doi:10.1371/journal.pbio.0020363 · Cited by 3,796
Flagged first, then by citations
Research works printed but not linked: 1
- Gao F., 2007, Oncol. Rep., 17, 123
Cited by
Sorted by citations
Items 201–300 of 886
Small and Long Non-Coding RNAs: Novel Targets in Perspective Cancer Therapy
Li, C. H., & Chen, Y. (2015) · Current Genomics · doi:10.2174/1389202916666150707155851 · Cited by 104
Role of MicroRNA in Proliferation Phase of Wound Healing
Soliman, A. M., Das, S., Ghafar, N. A., & Teoh, S. L. (2018) · Frontiers in Genetics · doi:10.3389/fgene.2018.00038 · Cited by 103
“miR-21 has been reported that miRNA plays a crucial role in cell proliferation, EMT and migration through silencing its target genes (Gabriely et al., 2008; Krichevsky and Gabriely, 2009).”
BackgroundInfluentialJung, H. M., Phillips, B. L., Patel, R. S., et al. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.366518 · Cited by 104
Han, L., Yue, X., Zhou, X., Lan, F., You, G., Zhang, W., Zhang, K., Zhang, C., Cheng, J., Yu, S., et al. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00344.x · Cited by 104
“Reports from our laboratory and others have identified roles for miR-21 in glioma cell apoptosis [28–31], invasion [21], and response to radiotherapy and chemotherapy [32–35], suggesting that miR-21 may be a good target for therapeutic intervention [36–38].”
BackgroundInfluentialCirculating MicroRNA-21 Is a Potential Diagnostic Biomarker in Gastric Cancer
Wu, J., Li, G., Wang, Z., Yao, Y., Chen, R., Pu, X.-Y., & Wang, J. (2015) · Disease Markers · doi:10.1155/2015/435656 · Cited by 102
“Particularly, since the miR-21-targeted genes identified till now are mostly tumor suppressors, miR-21 is closely related to various types of cancers including hepatocellular cancer [8], glioblastoma [9], glioma [10], and laryngeal carcinoma [11] and has been designated as an oncomir [12–14].”
BackgroundExpression, Tissue Distribution and Function of miR-21 in Esophageal Squamous Cell Carcinoma
Nouraee, N., Van Roosbroeck, K., Vasei, M., Semnani, S., Samaei, N. M., Naghshvar, F., Omidi, A. A., Calin, G. A., & Mowla, S. J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073009 · Cited by 103
“However, as we cannot exclusively point out miR-21 as the only liable molecule for this downregulation, our observations need future refinement [23,52].”
BackgroundMicroRNA-21: a therapeutic target for reversing drug resistance in cancer
Hong, L., Han, Y., Zhang, Y., Zhang, H., Zhao, Q., Wu, K., & Fan, D. (2013) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.2013.819853 · Cited by 104
“In addition, indirect regulation of Bcl-2, TIMP3 and MMP2 by miR-21 has also been reported [67].”
BackgroundRelevance of miR-21 in regulation of tumor suppressor gene PTEN in human cervical cancer cells
Peralta-Zaragoza, Ó., Deas, J., Meneses‐Acosta, A., De-la-O-Gómez, F., Fernández‐Tilapa, G., Gómez-Cerón, C., Benítez-Boijseauneau, O., Burguete-García, A. I., Torres-Poveda, K., Bermúdez-Morales, V. H., et al. (2016) · BMC Cancer · doi:10.1186/s12885-016-2231-3 · Cited by 105
“Inhibition of miR-21 can induce cell cycle arrest and increase chemosensitivity to anticancer agents, providing evidence that miR-21 may function as an oncogene in various human cancers [5, 7, 9, 19, 27].”
BackgroundMicroRNA-mediated breast cancer metastasis: from primary site to distant organs
Wang, L., & Wang, J. (2011) · Oncogene · doi:10.1038/onc.2011.444 · Cited by 102
Regulation of cancer metastasis by cell-free miRNAs
Alečković, M., & Kang, Y. (2014) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2014.10.005 · Cited by 101
“P A A uthor M anuscript Invasion & Migration Activity Targets Target cell Reference miR-221/222† Promote tumor induced angiogenesis P27/KIP1 TC [274] miR-378† Promotes tumor induced angiogenesis Sufu, Fus-1 TC [275] miR-494, miR-542-3p (exo) Establish pro-metastatic niche, enhance metastasis in vivo Mal, Cdh17, Traf4…”
BackgroundMethodInfluentialmiR-21 mediates nickel nanoparticle-induced pulmonary injury and fibrosis
Mo, Y., Zhang, Y., Wan, R., Jiang, M., Xu, Y., & Zhang, Q. (2020) · Nanotoxicology · doi:10.1080/17435390.2020.1808727 · Cited by 99
“Both membrane-anchored MMP inhibitor RECK and tissue inhibitor of metalloproteinases-3 (TIMP3) were confirmed to be targets of miR-21 (Gabriely et al. 2008; Jiang et al. 2019; Reis et al. 2012).”
BackgroundMiRNA inhibition in tissue engineering and regenerative medicine
Beavers, K. R., Nelson, C. E., & Duvall, C. L. (2014) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.12.006 · Cited by 101
Microarray analysis of microRNA expression in cutaneous squamous cell carcinoma
Sand, M. S., Skrygan, M., Georgas, D., Sand, D., Hahn, S. A., Gambichler, T., Altmeyer, P. J., & Bechara, F. G. (2012) · Journal of Dermatological Science · doi:10.1016/j.jdermsci.2012.09.004 · Cited by 99
“Reversion-inducing cysteine-rich protein with Kazal motifs (RECK) and tissue inhibitor of metalloproteinase 3 (Timp3), which are both tumor suppressors and inhibitors of matrix metalloproteinases (MMPs), as well as tumor suppressor programmed cell death 4 (PDCD4) and tropomyosin 1 (TPM1) have been shown to be downregu…”
BackgroundZhou, L., Yang, Z.-X., Song, W., Li, Q., Yang, F., Wang, D., Zhang, N., & Dou, K. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1965 · Cited by 102
A top-down view of the tumor microenvironment: structure, cells and signaling
Bhome, R., Bullock, M. D., AlSaihati, H., Goh, R. W., Primrose, J. M., Sayan, E., & Mirnezami, A. H. (2015) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2015.00033 · Cited by 101
The prognostic importance of miR-21 in stage II colon cancer: a population-based study
Kjær‐Frifeldt, S., Hansen, T. F., Nielsen, B. S., Joergensen, S. L., Lindebjerg, J., Soerensen, F. B., Christensen, R. D., & Jakobsen, A. K. M. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.365 · Cited by 97
“The miRNA-21 (miR-21) is consistently upregulated in many types of cancers including cancer of the colon (Slaby et al, 2007; Schetter et al, 2008), breast (Yan et al, 2008; Qian et al, 2009), lung (Markou et al, 2008), stomach (Chan et al, 2008) and glioblastoma (Gabriely et al, 2008).”
BackgroundMarsigliante, S. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1420 · Cited by 100
Sakai, A., & Suzuki, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.04.089 · Cited by 97
Loayza‐Puch, F., Yoshida, Y., Matsuzaki, T., Takahashi, C., Kitayama, H., & Noda, M. (2010) · Oncogene · doi:10.1038/onc.2010.23 · Cited by 97
“While this study was in progress, three papers proposing RECK as a potential target of miR-21 were published (Gabriely et al., 2008; Hu et al., 2008; Zhang et al., 2008).”
BackgroundXu, G., Zhang, Y., Wei, J., Jia, W. P., Ge, Z., Zhang, Z., & Liu, X. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-469 · Cited by 96
“Deregulated expressions of several miRNAs were found correlate with the pathologic and clinical characteristics of HCC [3]. miR-21, one of the most prominent miRNAs involved in the development and progression of many types of cancers, acts as an oncomir in the carcinogenesis of HCC through a mechanism of targeting mul…”
BackgroundInfluentialmiRNAs as molecular biomarkers of cancer
Fabbri, M. (2010) · Expert Review of Molecular Diagnostics · doi:10.1586/erm.10.27 · Cited by 94
Wong, T., Zhang, X., Zhuang, J. T.-F., Chan, H.-L., Li, C.-H., & Leung, G. (2012) · PubMed · Cited by 94
Expression profiles of miRNAs in human embryonic stem cells during hepatocyte differentiation
Kim, N., Kim, H. M., Jung, I., Kim, Y., Kim, D., & Han, Y. (2011) · Hepatology Research · doi:10.1111/j.1872-034x.2010.00752.x · Cited by 94
microRNA-21 modulates cell proliferation and sensitivity to doxorubicin in bladder cancer cells
Zhang, W. (2011) · Oncology Reports · doi:10.3892/or.2011.1245 · Cited by 93
The Roles of MicroRNAs in the Cancer Invasion-Metastasis Cascade
Le, X., Merchant, O., Bast, R. C., & Calin, G. A. (2010) · Cancer Microenvironment · doi:10.1007/s12307-010-0037-4 · Cited by 94
“Five members of the miR- Table 2 miRNAs involved in detachment and invasion miRNAs Targets Molecular regulation Deregulation in cancer Refs miR-29c collagen, laminin γ1, TDG, FUSIP1, SPARC ↓ cancer cell invasion Decreased [84] miR-31 frizzled3, MMP16, integrin a5, radixin, RhoA ↓ cancer cell adhesion/ migration/invasi…”
BackgroundMicroRNAs in cancer: Glioblastoma and glioblastoma cancer stem cells
Brower, J. V., Clark, P. A., Lyon, W., et al. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.06.002 · Cited by 91
“Further studies by Gabriely et al. (2008), have shown that miR-21 is a regulator of matrix metalloproteinase inhibitors (RECK and TIMP3) with implications in tissue invasion (Gabriely et al., 2008).”
BackgroundBelonging to a network—microRNAs, extracellular vesicles, and the glioblastoma microenvironment
Godlewski, J. A., Krichevsky, A. M., Johnson, M. D., Chiocca, E. A., & Bronisz, A. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou292 · Cited by 92
Self-citationProblems of glioblastoma multiforme drug resistance
Stavrovskaya, A. A., Сакенович, Ш. С., & Rybalkina, E. Y. (2016) · Biochemistry (Moscow) · doi:10.1134/s0006297916020036 · Cited by 95
Bhatti, I. K., Lee, A., James, V. H., Hall, R. I., Lund, J. N., Tufarelli, C., Lobo, D. N., & Larvin, M. (2010) · Journal of Gastrointestinal Surgery · doi:10.1007/s11605-010-1381-x · Cited by 91
“Furthermore, knockdown studies of miR-21 have confirmed its oncogenic role in cancer cell lines by inducing growth suppression and upregulation of tumour suppressors such as phosphate and tensin homolog,(22) tropomyosin alpha-1 chain(23) and reversion-inducing cysteine-rich protein with kazal.(24)”
BackgroundChen, M., Liu, Y., Varley, P. R., Chang, Y., He, X.-X., Huang, H., Tang, D., Lotze, M. T., Lin, J., & Tsung, A. (2015) · Cancer Research · doi:10.1158/0008-5472.can-14-2147 · Cited by 89
“Previous work from other groups has also shown that MMP activity can be used as amarker of disease progression in animal tumormodels (46, 47).”
BackgroundThe MiRNA Journey from Theory to Practice as a CNS Biomarker
Stoicea, N., Du, A., Lakis, D. C., Tipton, C. B., Arias-Morales, C. E., & Bergese, S. D. (2016) · Frontiers in Genetics · doi:10.3389/fgene.2016.00011 · Cited by 91
Targeting miRNAs by polyphenols: Novel therapeutic strategy for cancer
Devi, K. P., Rajavel, T., Daglia, M., Nabavi, S. F., Bishayee, A., & Nabavi, S. M. (2017) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2017.02.001 · Cited by 90
TIMP3 regulates migration, invasion and in vivo tumorigenicity of thyroid tumor cells
Anania, M. C., Sensi, M., Radaelli, E., Miranda, C., Vizioli, M. G., Pagliardini, S., Favini, E., Cleris, L., Supino, R., Formelli, F., et al. (2011) · Oncogene · doi:10.1038/onc.2011.18 · Cited by 89
“Evidence is emerging that downregulation of TIMP3 expression in tumors can be achieved also through deregulation of microRNAs, as TIMP3 is a target of several microRNAs upregulated in human tumors such as miR21, miR181b, miR221 and 222 (Gabriely et al., 2008; Garofalo et al., 2009; Wang et al., 2010).”
BackgroundQu, J., LI, M., An, J., Zhao, B., Zhong, W., Gu, Q., Cao, L., Yang, H., & Hu, C. (2015) · International Journal of Oncology · doi:10.3892/ijo.2015.3187 · Cited by 89
Shishodia, G., Shukla, S., Srivastava, Y., Masaldan, S., Mehta, S., Bhambhani, S., Sharma, S. B., Mehrotra, R., Das, B. C., & Bharti, A. C. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0385-2 · Cited by 87
“TIMP-3 contains a putative consensus miR-21 binding site that plays a key role in regulating the TIMP-3 transcripts by miR-21 [44].”
BackgroundRegulation of TIMP3 in diabetic nephropathy: a role for microRNAs
Fiorentino, L., Cavalera, M., Mavilio, M., Conserva, F., Menghini, R., Gesualdo, L., & Federici, M. (2013) · Acta Diabetologica · doi:10.1007/s00592-013-0492-8 · Cited by 88
“TIMP3 expression is regulated by a number of miRs such as miR-21, miR-181b, miR-182, miR-216 and miR-221/2, expressed in a tissue or cell specific manner [23, 24].”
BackgroundMiR‐483–5p suppresses the proliferation of glioma cells via directly targeting ERK1
Wang, L., Shi, M., Hou, S., Ding, B., Liu, L., Ji, X., Zhang, J., & Deng, Y. (2012) · FEBS Letters · doi:10.1016/j.febslet.2012.03.035 · Cited by 87
Blockage of a miR-21/EGFR regulatory feedback loop augments anti-EGFR therapy in glioblastomas
Zhang, K.-L., Han, L., Chen, L., Shi, Z., Yang, M., Ren, Y., Chen, L., Zhang, J., Pu, P., & Kang, C. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.08.043 · Cited by 87
miRNA-21 as a novel therapeutic target in lung cancer
Lianidou, E. S., Markou, A. N., & Zavridou, M. (2016) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s60341 · Cited by 88
“51,70 ReCK miR-21 regulation of RECK expression was detected in several types of cancer such as in glioma 71 and in prostate cancer.”
Dong, C., Wu, W. K. K., Feng, S., WANG, X. J., Shao, J., & Qiao, J. (2012) · International Journal of Oncology · doi:10.3892/ijo.2012.1542 · Cited by 89
Role of microRNAs in gliomagenesis: targeting miRNAs in glioblastoma multiforme therapy
Nikaki, A. V., Piperi, C., & Papavassiliou, A. G. (2012) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2012.710199 · Cited by 84
“1 Changes of miRNAs’ expression in glioblastomas Multiple microarray studies have shown significant changes in the expression patterns of various miRNAs in GBM tissues and cell lines, with many of them that have no beneficial role for growth and migration of glioma cells being downregulated [52-86].”
BackgroundInfluentialScilabra, S. D., Troeberg, L., Yamamoto, K., Emonard, H., Thøgersen, I. B., Enghild, J. J., Strickland, D. K., & Nagase, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.393322 · Cited by 89
Exosome-based immunomodulation during aging: A nano-perspective on inflamm-aging
Prattichizzo, F., Micolucci, L., Cricca, M., Carolis, S. D., Mensa’, E., Ceriello, A., Procopio, A. D., Bonafè, M., & Olivieri, F. (2017) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2017.02.008 · Cited by 86
MicroRNAs in colorectal cancer: Small molecules with big functions
Yu, X., Yang, H., Zhao, L., Lau, W. B., Lau, B., Ren, N., Hu, Y., Yi, T., Zhao, X., Zhou, S., et al. (2014) · Cancer Letters · doi:10.1016/j.canlet.2014.11.051 · Cited by 84
Lin, H.-Y., Chiang, C.-H., & Hung, W. (2013) · British Journal of Cancer · doi:10.1038/bjc.2013.349 · Cited by 78
“Interestingly, RECK has been demonstrated to be a repression target of several miRNAs including miR-21, miR-372/373, miR-222, miR-7 and miR-182 (Gabriely et al, 2008; Hu et al, 2008; Zhang et al, 2008; Loayza-Puch et al, 2010; Hirata et al, 2012; Jung et al, 2012; Li et al, 2012).”
BackgroundMicroRNAs in cancer treatment and prognosis.
Schoof, C. R. G., Botelho, E. L. D. S., Izzotti, A., & Vasques, L. R. (2012) · Europe PMC (PubMed Central) · Cited by 82
DEAD-box RNA helicase DDX23 modulates glioma malignancy via elevating miR-21 biogenesis
Yin, J., Park, G., Lee, J. E., Choi, E. Y., Park, J. Y., Kim, T. H., Park, N., Jin, X. J., Jung, J.-E., Shin, D., et al. (2015) · Brain · doi:10.1093/brain/awv167 · Cited by 85
“…cell line by guest on S eptem ber 3, 2015 D ow nloaded from were largely similar to the miR-21-mediated phenotypes, such as cell proliferation and invasion, previously observed by our group and others (Gabriely et al., 2008; Papagiannakopoulos et al., 2008; Kim et al., 2011; Kwak et al., 2011).”
BackgroundRole of microRNAs in glioblastoma
Chen, M., Medarova, Z., & Moore, A. (2021) · Oncotarget · doi:10.18632/oncotarget.28039 · Cited by 84
“By targeting MMPs, Ras/Raf, and ERK, miR-21 increases the invasive potential of GBM cells [77, 85, 87].”
BackgroundDiscovery of Inhibitors of MicroRNA-21 Processing Using Small Molecule Microarrays
Connelly, C. M., Boer, R. E., Moon, M. H., Gareiss, P. C., & Schneekloth, J. S. (2016) · ACS Chemical Biology · doi:10.1021/acschembio.6b00945 · Cited by 83
Abdel‐Hamid, N. M., & Abass, S. A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06635-z · Cited by 86
Wong, H. K., Fatimy, R. E., Onodera, C. S., Wei, Z., Yi, M., Mohan, A., Gowrisankaran, S., Karmali, P. P., Marcusson, E. G., Wakimoto, H., et al. (2015) · Molecular Therapy · doi:10.1038/mt.2015.72 · Cited by 80
Self-citationTherapeutic strategies for inhibiting invasion in glioblastoma
Drappatz, J., Norden, A. D., & Wen, P. Y. (2009) · Expert Review of Neurotherapeutics · doi:10.1586/ern.09.10 · Cited by 80
microRNAs in Gliomas: Small Regulators of a Big Problem
Silber, J., James, C. D., & Hodgson, J. (2009) · NeuroMolecular Medicine · doi:10.1007/s12017-009-8087-9 · Cited by 80
“Interestingly, reduced in vitro invasion and motility by miR-21-LNAs could be partially rescued upon co-transfection with RECK siRNAs, suggesting that RECK is the major factor that mediates miR-21 motility and invasion in U87 cells in vitro (Gabriely et al. 2008).”
BackgroundCosta, P. M., Cardoso, A. L., Nóbrega, C., Pereira de Almeida, L. F., Bruce, J. N., Canoll, P., & Pedroso de Lima, M. C. (2013) · Human Molecular Genetics · doi:10.1093/hmg/dds496 · Cited by 80
Barski, D., Wolter, M., Reifenberger, G., et al. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2009.00340.x · Cited by 79
“Also miR-21 has been indicated to downregulate TIMP3 expression in glioma cells in vitro and in a glioma model in nude mice (14).”
BackgroundRen, J., Zhu, D., Liu, M., Sun, Y., & Tian, L. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.07.047 · Cited by 79
Hold on or Cut? Integrin- and MMP-Mediated Cell–Matrix Interactions in the Tumor Microenvironment
Niland, S., & Eble, J. A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms22010238 · Cited by 87
M i R ‐21 Modulates h TERT Through a STAT 3‐Dependent Manner on Glioblastoma Cell Growth
Wang, Y., Sun, G., Luo, H., Wang, X., Lan, F., Yue, X., Fu, L., Pu, P., Kang, C., Liu, N., et al. (2012) · CNS Neuroscience & Therapeutics · doi:10.1111/j.1755-5949.2012.00349.x · Cited by 78
“In addition, miR-21 regulated matrix metalloproteinase (MMP) activities by targeting MMP inhibitors reversion-inducing cysteine-rich protein with kazal motifs (RECK) and tissue inhibitor of metalloproteinases 3 (TIMP-3) to contribute to glioma malignant phenotype [8].”
Nedaeinia, R., Sharifi, M., Avan, A., Kazemi, M., Rafiee, L., Ghayour‐Mobarhan, M., & Salehi, R. (2016) · Cancer Gene Therapy · doi:10.1038/cgt.2016.25 · Cited by 78
Alterations of MicroRNAs Contribute to Colon Carcinogenesis
Schetter, A. J., & Harris, C. C. (2011) · Seminars in Oncology · doi:10.1053/j.seminoncol.2011.08.009 · Cited by 78
Zhou, X., Ren, Y., Liu, A., Han, L., Zhang, K., Li, S., Li, P., Li, P., Kang, C., Wang, X., et al. (2014) · Oncology Reports · doi:10.3892/or.2014.3114 · Cited by 76
MicroRNAs in Skin and Wound Healing
Banerjee, J., & Sen, C. K. (2012) · Methods in molecular biology · doi:10.1007/978-1-62703-083-0_26 · Cited by 79
Nie, J., Li, T.-X., Zhang, X., & Liu, J. (2019) · Non-Coding RNA · doi:10.3390/ncrna5020036 · Cited by 76
“Regarding the mechanism of action, miR-21 could effect a variety of cellular and molecular pathways such as insulin-like growth factor (IGF)-binding protein-3 (IGFBP3) RECK, TIMP3, MMP, and PDCD4 [46,47,49].”
BackgroundThe Role of microRNA-21 in the Onset and Progression of Cancer
Singh, A. K., Singh, A. K., Giri, R., Kumar, D., Sharma, R., Vališ, M., Kuča, K., & Garg, N. (2021) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0096 · Cited by 81
Hu, A., Huang, J., Xu, W., Jin, X., Li, J., Tang, Y., Huang, X., Cui, H., & Sun, G.-B. (2014) · Europe PMC (PubMed Central) · Cited by 74
Wagenaar, T. R., Zabludoff, S., Ahn, S., Allerson, C. R., Arlt, H., Baffa, R., Cao, H., Davis, S. P., García-Echeverría, C., Gaur, R., et al. (2015) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-14-0703 · Cited by 74
“Immediately before implantation in vivo, on-target inhibition of miR-21 was confirmed by analyzing levels of endogenous miR-21 targets ANKRD46, DDAH1, and RECK (Fig.”
BackgroundMethodInfluentialHeavy Metals and Epigenetic Alterations in Brain Tumors
Caffo, M., Caruso, G., Fata, G. L., Barresi, V., Visalli, M., Venza, M., & Venza, I. (2015) · Current Genomics · doi:10.2174/138920291506150106151847 · Cited by 74
“The formation of free radical can be directed including H2O2, and hydroperoxides or by reducing cell antioxidants [67].”
BackgroundMicroRNA-21 as a potential colon and rectal cancer biomarker
Li, T. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i34.5615 · Cited by 74
Dangi-Garimella, S. Y., Strouch, M. J., Grippo, P. J., Bentrem, D. J., & Munshi, H. G. (2010) · Oncogene · doi:10.1038/onc.2010.485 · Cited by 72
“Finally, even though microRNAs can regulate MMP expression and function (Gabriely et al., 2008; Roy et al., 2009), it was not heretofore shown that MMPs could in turn modulate microRNAs.”
Matrix Metalloproteinases and Their Inhibitors in Chronic Obstructive Pulmonary Disease
Navrátilová, Z., Kolek, V., & Petřek, M. (2015) · Archivum Immunologiae et Therapiae Experimentalis · doi:10.1007/s00005-015-0375-5 · Cited by 74
“In addition, the decreased expression of PTEN is related to its gene hypermethylation in COPD (Vucic et al. 2014).”
BackgroundInfluentialThe role of microRNA in the pathogenesis of glial brain tumors
Beylerli, O., Фанилевич, Г. И., Sufianov, A. A., Ilyasova, T., & Zhang, F. (2022) · Non-coding RNA Research · doi:10.1016/j.ncrna.2022.02.005 · Cited by 72
“Currently, the trigger for these immune responses is unclear, and preclinical trials may need to be repeated [52].”
BackgroundMethodInfluentialMicroRNA Silencing in Primates: Towards Development of Novel Therapeutics
Petri, A., Lindow, M., & Kauppinen, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2749 · Cited by 71
Javadian, M., Gharibi, T., Shekari, N., Abdollahpour‐Alitappeh, M., Mohammadi, A., Hossieni, A., Mohammadi, H., & Kazemi, T. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27445 · Cited by 71
“Finally, miR‐30b, miR‐30c, miR‐30d, miR‐21, miR‐214, and miR‐206 can target TIMP‐2 and TIMP‐3 mRNAs (Garbacki et al., 2011).”
BackgroundInfluentialChusorn, P., Namwat, N., Loilome, W., Techasen, A., Pairojkul, C., Khuntikeo, N., Dechakhamphu, A., Talabnin, C., Chan-on, W., Ong, C. K., et al. (2013) · Tumor Biology · doi:10.1007/s13277-013-0688-0 · Cited by 73
“targets such as the metastasis suppressor protein RECK [31, 58] and the pro-apoptotic factor PTEN [19], which have been reported to be down-regulated in CCA [59, 60].”
BackgroundMicro RNA s and lymphomagenesis: a functional review
Lawrie, C. H. (2012) · British Journal of Haematology · doi:10.1111/bjh.12157 · Cited by 71
“…in hepatocellular cancer and NK/T cell lymphoma (Meng et al, 2007; Yamanaka et al, 2009), tissue inhibitor of metalloproteinase-3 (TIMP3) in glioma (Gabriely et al, 2008), tumour suppressor genes ANP32A and SMAR- CA4 in B-cell lymphoma (Schramedei et al, 2011), and multiple components of the TP53,…”
BackgroundSun, S.-S., Zhou, X., Huang, Y.-Y., Kong, L.-P., Mei, M., Guo, W.-Y., Zhao, M.-H., Ren, Y., Shen, Q., & Zhang, L. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0487-x · Cited by 72
“It was reported that miR-21 targets a number of important molecules such as PTEN, PDCD4, TIMP3 and TMP1 [35, 36].”
BackgroundFan, X., Wang, E., Wang, X., Cong, X., & Chen, X. (2014) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2014.02.009 · Cited by 73
Epigenetic regulation of matrix metalloproteinases and their collagen substrates in cancer
Chernov, A. V., & Strongin, A. Y. (2011) · bmc · doi:10.1515/bmc.2011.017 · Cited by 69
“miR-10b MMP-14 GBM (94) miR-143 MMP-13 Osteosarcoma (95) miR-146b MMP-16 GBM (96) miR-181b TIMP-3 Hepatocellular carcinoma (97) miR-206 MMP-2/MMP-9 Breast carcinoma (98) miR-216a Type II collagen Renal mesangial cells (99) miR-218 MMP-9 GBM (100) miR-21 TIMP-3 Cholangiocarcinoma, GBM, breast carcinoma (93, 101, 102) m…”
BackgroundThe role of MiRNA-21 in gliomas: Hope for a novel therapeutic intervention?
Aloizou, A.-M., Pateraki, G., Siokas, V., Mentis, A.-F. A., Liampas, I., Lazopoulos, G., Kovatsi, L., Mitsias, P. D., Bogdanos, D. P., Paterakis, K., et al. (2020) · Toxicology Reports · doi:10.1016/j.toxrep.2020.11.001 · Cited by 69
“the main features that are evaluated in appointing a grade IV to a glioma, and, to this end, they studied this notion further [7]; their findings are discussed in the sections to follow.”
BackgroundResultInfluentialQu, S., Guan, J., & Liu, Y. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.11.036 · Cited by 69
“Moreover, through targets with PTEN or PDCD4, miR-21 acts as an oncogene in glioma [40,41].”
BackgroundXie, L., Wu, M., Lin, H., et al. (2014) · Molecular BioSystems · doi:10.1039/c3mb70564a · Cited by 69
MicroRNAs and glioblastoma: roles in core signalling pathways and potential clinical implications
Šáňa, J., Hajdúch, M., Michálek, J., Vyzula, R., & Slabý, O. (2011) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2011.01317.x · Cited by 69
“2) [24].”
miR-139-5p suppresses cancer cell migration and invasion through targeting ZEB1 and ZEB2 in GBM
Yue, S., Wang, L., Zhang, H., Min, Y., Lou, Y., Sun, H., Jiang, Y., Zhang, W., Aming, L., Guo, Y., et al. (2015) · Tumor Biology · doi:10.1007/s13277-015-3372-8 · Cited by 68
Kreth, S., Thon, N., & Kreth, F. W. (2012) · Cancer Letters · doi:10.1016/j.canlet.2012.04.008 · Cited by 68
“miR-21 promoting invasion by targeting regulators of matrix metalloproteinases, miR-26a targeting PTEN, and miR-10b and miR-221 targeting cell cycle inhibitors, and miR-30e targeting IjBa [84–90].”
BackgroundWang, M., Wang, Y., Xia, Y., et al. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9099-0 · Cited by 68
“expression [31–35].”
Prognostic Role of microRNA-21 in Colorectal Cancer: a Meta-Analysis
Xia, X., Yang, B., Zhai, X., Liu, X., Shen, K., Wu, Z., & Cai, J. (2013) · PLoS ONE · doi:10.1371/journal.pone.0080426 · Cited by 69
“The oncogenic role of miR-21 is showed by targeting several tumor suppressor genes including include programmed cell death 4 (PDCD4) [9,34], phosphatase and tensin homolog (PTEN) [33], cell division cycle 25 homolog A (Cdc25a) [37], reversion-inducing cysteine-rich protein with kazal motifs (RECK) [38], and tropomyosi…”
BackgroundIsmail, A., El‐Mahdy, H. A., Abulsoud, A. I., Sallam, A.-A. M., Eldeib, M. G., Elsakka, E. G. E., Zaki, M. B., & Doghish, A. S. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.10.241 · Cited by 67
Bai, X., & Bian, Z. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.842288 · Cited by 66
Prathipati, P., Nandi, S. S., & Mishra, P. K. (2016) · Stem Cell Reviews and Reports · doi:10.1007/s12015-016-9696-y · Cited by 66
Circulating MicroRNA Biomarkers for Glioma and Predicting Response to Therapy
Tumilson, C. A., Lea, R. W., Alder, J. E., & Shaw, L. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8679-8 · Cited by 65
“MiR-21 promotes migration and invasion by targeting MMP inhibitors RECK and TIMP3 [60]; miR-15b is a cell cycle regulator which targets CCNE1 [61] (Fig.”
BackgroundLi, D., Chen, P., Li, X., Zhang, L., Xiong, W., Zhou, M., Xiao, L., Fang, Z., Li, X., Wu, M., et al. (2011) · OMICS A Journal of Integrative Biology · doi:10.1089/omi.2011.0064 · Cited by 66
“…tumor suppressor PDCD4, promotion of invasion by targeting MMP inhibitors RECK and TIMP3, and even mediation of che-moresistance to the chemotherapeutic agent VM-26 by targeting NF-j B signaling inhibitor LRRFIP1 (Chan et al., 2005; Chen et al., 2008; Gabriely et al., 2008; Li et al., 2009).”
Epigenetic regulation of mmp-9 gene expression
Labrie, M., & St‐Pierre, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1214-z · Cited by 65
“[118], who showed that miR-21, which is upregulated in glioblastoma, downregulates the expression of RECK and timp3 mRNA.”
Laginestra, M. A., Cascione, L., Motta, G., Fuligni, F., Agostinelli, C., Rossi, M., Sapienza, M. R., Righi, S., Broccoli, A., Indio, V., et al. (2019) · Modern Pathology · doi:10.1038/s41379-019-0279-8 · Cited by 66
Mafi, A., Rahmati, A., Babaei Aghdam, Z., Salami, R., Salami, M., Vakili, O., & Aghadavod, E. (2022) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-022-00354-4 · Cited by 56
“miRNAs are perfect molecules in this context, with the ability to be secreted from tumor cells within extracellular vesicles [8, 24].”
BackgroundInfluentialBerezin, V., Walmod, P. S., Filippov, M. A., & Dityatev, A. E. (2014) · Progress in brain research · doi:10.1016/b978-0-444-63486-3.00015-3 · Cited by 62
Paik, W. H., Kim, H. R., Park, J. K., et al. (2013) · PubMed · Cited by 65
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja, H., Thies, K., Taffany, D. A., Deighan, C., Liu, T., Yu, L., Fernández, S., Shapiro, C. L., Otero, J. J., Timmers, C. D., et al. (2014) · Oncogene · doi:10.1038/onc.2014.294 · Cited by 66
MetastamiRs: Non-Coding MicroRNAs Driving Cancer Invasion and Metastasis
López‐Camarillo, C., Marchat, L. A., Aréchaga-Ocampo, E., Pérez‐Plasencia, C., Moral-Hernández, Ó. D., Castaneda-Ortiz, E. J., & Rodriguez-Cuevas, S. A. (2012) · International Journal of Molecular Sciences · doi:10.3390/ijms13021347 · Cited by 67
MicroRNA-21 suppression impedes medulloblastoma cell migration
Grunder, E., D’Ambrosio, R., Fiaschetti, G., Abela, L., Arcaro, A., Zuzak, T. J., Ohgaki, H., Lv, S., Shalaby, T., & Grotzer, M. A. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2011.06.041 · Cited by 66
“In support of our observations we can refer to recent studies that identified TIMP as a functional target of miR-21 in cell invasion and metastasis in glioma and cholangiocarcinoma.(53) Another important membrane protein that mediates degradation of extracellular matrix components and is regulated by the expression of…”
miR-200c inhibits invasion and migration in human colon cancer cells SW480/620 by targeting ZEB1
Chen, M. L., Liang, L. S., & Wang, X. K. (2012) · Clinical & Experimental Metastasis · doi:10.1007/s10585-012-9463-7 · Cited by 66
“Recently, some studies have described altered microRNAs expression which affects metastasis in breast cancer, colorectal cancer and glioma [17, 18, 25, 26].”
Metadata
- Authors
- Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., & Krichevsky, A. M.
- Affiliations
- Brigham and Women's Hospital (US)
- Harvard University (US)
- Regulus Therapeutics (United States) (US)
- Corresponding author
- Krichevsky, Anna M.
- ORCID
- Venue
- Molecular and Cellular Biology
- Publisher
- Informa UK Limited
- Published
- 2008-09-01
- Volume
- 28
- Issue
- 17
- Pages
- 5369-5380
- ISSN
- 0270-7306 (ISSN-L)
- 1098-5549
- PMC
- PMC2519720
- OpenAlex
- W2163655902
- Cited by
- 888
- References
- 62
- Citations by year
- 2026: 13 · 2025: 19 · 2024: 21 · 2023: 29 · 2022: 20 · 2021: 21 · 2020: 43 · 2019: 41 · 2018: 33 · 2017: 56 · 2016: 56 · 2015: 75 · 2014: 76 · 2013: 86 · 2012: 91
- FWCI
- 21.02
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Molecular and Cellular Biology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- PubMed Central (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institutes of Health (CA86355)
- National Cancer Institute (R21 CA116141, P50 CA86355-04, P50CA086355)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › MicroRNA in disease regulation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Protease and Inhibitor Mechanisms
- Health Sciences › Medicine › Oncology › Glioma Diagnosis and Treatment
- Keywords
- miR-21, glioma invasion, glioblastoma, matrix metalloproteinases, RECK, TIMP-3, matrix metalloproteinase inhibitors, cell migration, apoptosis, antisense oligonucleotides, microRNA inhibition, tumor malignancy
- MeSH terms
- Animals, Base Sequence, Cell Movement, Enzyme Inhibitors, Extracellular Matrix, Glioma, Humans, Molecular Sequence Data, Neoplasm Invasiveness, Neoplasm Transplantation, RNA, Messenger, Down-Regulation, Gene Expression Regulation, Neoplastic, Apoptosis, Disease Progression, Oligonucleotide Array Sequence Analysis, Matrix Metalloproteinases, Gene Expression Profiling, MicroRNAs, Cell Line, Tumor, Mice, Genes, Neoplasm, Matrix Metalloproteinase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-10-19, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-19 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review